Moderna Missed No Mark: Q3 Revenue Up 29% & Intismeran Shows Promise
Moderna reported robust Q3 2026 revenue of $1.3 billion and raised 2026 full-year growth expectations to 15%-25%. The update highlights the U.S. approval of mFLUSIVA and positive Phase 3 data for intismeran, exceeding analyst forecasts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed